Pricing Log in Create free account
Friday 6 November 2026 Export AZTR’s income statement to Excel — free account

Azitra, Inc.

AZTR Healthcare Biotechnology

Azitra, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7,500.00, down 98.9% from fiscal 2023.

EPS
+85.3%
Free cash flow
−19.6%

Quarter to June 2026, against a year earlier

0.75 0.02 +2.74%
Market cap
$4.4M
P/E
1.3×
Fwd P/E
−0.1×
Dividend yield
—
F-score
3/9
Altman Z
−14.66
Beneish M
13.02
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 4.39
Revenue ttm 0.58
Net income ttm (12.27)
Free cash flow ttm (11.39)
Net debt Q (6.73)
Valuation
P/E 1.27
Forward P/E (0.07) (negative: loss-making)
Price / sales 2.50
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.20
Financial health
Current ratio Q 4.86 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (2,442.29)
Growth
Revenue growth Q −93.38% (below 0%: shrinking)
Operating income growth Q −19.08% (below 0%: shrinking)
EPS, this year +90.89% (at or above 15%: strong)
EPS, next year A +68.78% (at or above 15%: strong)
Revenue, next year A +6.67%
EPS, past 5 yrs —
EPS, next 5 yrs A +69.96% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −9.1×, against a ten-year median of −0.9×; over the ten years it ranged from −11.2× in 2026 to 21.6× in 2023.
P/S against its own 10 years 24.44%
10-year low 10-year high
P/B against its own 10 years 3.22%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 2 5 2 7
Receivables 0 0 0 0
Inventory — — — —
Other — — — —
3 5 3 7
2023 2024 2025 Q'26
Payables 1 0 0 0
ST’ Debt — — — —
Other — — 0 —
2 1 1 2

Compound Annual Growth %

10y 5y 3y
Sales — — (59.15%)
Cash Flow — — 0.00%
Earnings — — 0.00%
Book Value — — 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −2.10 Actual −1.70

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY24 −31.96 −11.32 Beat by 20.64
Q2 FY25 −13.98 −11.98 Beat by 2.00
Q3 FY25 −7.90 −6.70 Beat by 1.20
Q2 FY26 −2.10 −1.70 Beat by 0.40
Q3 FY26 −0.20 — Reports 11 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (2.53) (1.73) — — —
’25 (15.51) (11.82) (6.71) 11.57 (22.48)
’24 (287.63) (182.51) (11.42) 324.55 (157.00)
’23 (4.65k) (4.12k) (320.84) 5.82k (3.27k)
’22 (5.71k) (3.58k) (4.58k) — (20.23k)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’24 — 0 — — 0
’23 0 0 0 0 1
’22 0 0 0 — 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (3) — — —
’25 (3) (3) (2) (3) (11)
’24 (3) (2) (2) (3) (10)
’23 (1) (2) (2) (3) (7)
’22 (2) (4) (2) (2) (8)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (3) — — —
’25 (3) (3) (2) (3) (11)
’24 (3) (2) (3) (3) (11)
’23 (1) (2) (2) (3) (8)
’22 (2) (4) (2) (2) (9)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — — 0 0 1 0 — 1 (59.1%) 0 — — —
Gross margin, % — — — — — 22.91 100.00 100.00 100.00 — 100.00 +77.1 pt
EBT — — — — — (9) (11) (11) (9) (11) (12) +5.2%
EBT margin, % — — — — — (8,127.00) (3,760.70) (1,642.35) (119,446.67) 0.00 0.00 +8,127.0 pt
Net income — — — — — (9) (11) (11) (9) (11) (12) +5.2%
Per share, $
Per share, $ Revenue — — — — — 0.01 568.00 196.00 0.13 0.00 0.00 n/m
Earnings — — — — — (0.97) (20,232.77) (3,268.21) (157.00) (22.48) 0.59 +119.4%
Cash flow — — — — — (0.67) (16,699.00) (2,103.54) (178.35) (23.03) (5.75) +142.4%
Capex — — — — — 0.00 (673.60) (90.94) (6.64) (0.38) (0.14) n/m
Free cash flow — — — — — (0.67) (17,372.60) (2,194.49) (184.99) (23.40) (5.90) +143.3%
Book value — — — — — (2.13) (72,520.60) 832.31 99.80 7.80 3.80 n/m
Shares, m — — — — — 12 0 0 0 0 1 (55.2%)
Valuation, ×
Valuation, × P/E — — — — — 0.00 0.00 0.00 0.00 — 1.27 0.0
P/S — — — — — 13.46 13.46 10.70 2.79 — 2.50 10.1
P/B — — — — — 0.00 0.00 2.52 0.28 — 0.20 0.7
EV/Sales — — — — — 28.00 28.00 8.12 (5.04) — (9.10) 14.8
EV/FCF — — — — — (1.02) (1.02) (0.73) 0.28 — 0.46 (0.6)
Cash, $m
Cash, $m Operating cash flow — — — — — (8) (8) (7) (10) (11) (11) +8.6%
Capex — — — — — (1) 0 0 0 0 0 (27.2%)
Free cash flow — — — — — (8) (9) (8) (11) (11) (11) +9.0%
Balance, $m
Balance, $m Working capital — — — — — 7 2 1 4 2 6 (28.0%)
Net debt — — — — — 27 3 (2) (5) (2) (7) n/m
Shareholders’ equity — — — — — (26) (36) 3 6 4 7 n/m
Returns, %
Returns, % ROA — — — — — 0.00 (154.87) (205.80) (143.78) (176.93) (190.69) (176.9) pt
ROIC — — — — — 0.00 0.00 (407.29) (595.10) (395.49) (1,272.49) (395.5) pt
ROE — — — — — 0.00 43.37 75.80 (208.27) (230.65) (256.67) (230.7) pt
People
People Employees — — — — — — 10 10 12 13 — +9.1%
Revenue/emp, $m — — — — — 0.00 0.03 0.07 0.00 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2024 · latest quarter Jun 2024 · fundamentals updated 2 Nov 2026

Azitra, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NIKI Niki BioSolutions, Inc. $4.7M — (loss-making) 31.9× −32.36% (below 0%: shrinking) +69.51% (above 0%: growing) +58.14% (above 0%: growing) (154.22%) 0.00% Compare
SKYE Skye Bioscience, Inc. $4.6M — (loss-making) — −34.71% (below 0%: shrinking) n/m +34.84% (above 0%: growing) 72.71% 0.00% Compare
AZTR Azitra, Inc. $4.4M 1.3× — (loss-making) −93.38% (below 0%: shrinking) n/m −19.55% (below 0%: shrinking) 100.00% 0.00%
ADTX Aditxt, Inc. $4.4M — (loss-making) — +1,120.00% (above 0%: growing) n/m +60.82% (above 0%: growing) 23.77% (35,753.28%) Compare
XBIO Xenetic Biosciences, Inc. $4.4M — (loss-making) — (loss-making) +11.99% (above 0%: growing) n/m −128.11% (below 0%: shrinking) 100.00% (147.09%) Compare
OSRH OSR Health, Inc. $4.1M — (loss-making) — −72.20% (below 0%: shrinking) n/m −398.76% (below 0%: shrinking) 27.43% (960.69%) Compare
NCNA NuCana PLC Sponsored ADR $4.0M — (loss-making) — — n/m +55.66% (above 0%: growing) 0.00% 0.00% Compare
PMCB Nuvilex Inc. $4.0M — (loss-making) — −103.94% (below 0%: shrinking) n/m +60.84% (above 0%: growing) 100.00% 0.00% Compare
CELZ Creative Medical Technology Holdings, Inc. $4.0M — (loss-making) — (loss-making) 0.00% n/m −27.05% (below 0%: shrinking) 66.67% 0.00% Compare
Median of peers $4.2M — — −32.36% — +45.25% 47.05% 0.00%

All 621 Biotechnology stocks →

Azitra, Inc. (AZTR) Latest News

2 Nov

Impact 3 · · Zacks Small Cap Research

29 Oct

Impact 4 · · PR Newswire

26 Oct

Impact 4 · · PR Newswire

16 Oct

Impact 3 · · PR Newswire

28 Sep

Impact 4 ·

12 Aug

Impact 3 ·

15 Jul

Impact 3 ·

17 Jun

Impact 4 ·
Impact 4 ·

13 May

Impact 4 · · PR Newswire

6 May

Impact 4 · · PR Newswire

19 Mar

Impact 4 ·

13 Mar

Impact 4 · · PR Newswire

27 Feb

Impact 4 · · PR Newswire

24 Feb

Impact 4 ·

7 Jan

Impact 3 ·

17 Dec

Impact 3 · · PR NewswireMT NewswiresMT NewswiresGuruFocus.comStockStorySimply Wall St.StockStoryMotley Fool

24 Nov

Impact 3 · · PR Newswire

18 Nov

Impact 4 · · Zacks Small Cap ResearchClinical Trials ArenaGuruFocus.comGuruFocus.comZacksGuruFocus.com

12 Nov

Impact 4 · · PR NewswireAssociated Press FinanceGuruFocus.comGuruFocus.comGuruFocus.comAssociated Press FinanceZacksGuruFocus.com

20 Oct

Impact 4 · · PR Newswire

15 Oct

Impact 3 · · PR NewswireMT NewswiresSimply Wall St.MT NewswiresMotley Fool

3 Oct

Impact 3 · · PR Newswire

27 Aug

Impact 4 · · GuruFocus.com
Impact 4 · · PR Newswire

25 Aug

Impact 4 ·

11 Aug

Impact 4 ·
Impact 3 ·

10 Jun

Impact 3 ·

28 May

Impact 4 · · PR Newswire
stockrow.com/AZTR · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com